Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 3
Opinion
Video
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
Author(s):
Key Takeaways
- PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions.
- Investigational agents in BCG-naive and unresponsive settings include gene therapy and intravesical treatments, targeting enhanced immune activation.
EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Now Viewing
EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Video content above is prompted by the following:
- What is the role of the PD-1/PD-L1 pathways in cancer immunotherapy?
- What are their mechanisms of action?
What agents are being investigated in the BCG-naive and unresponsive setting? Gene therapy, intravesical?
Related Videos
Related Content
